Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency
The DOI matches its Crossref record.
Abstract
The physiological significance of the hyperglucagonemia that occurs in patients with many catabolic conditions is unclear. The effect of hyperglucagonemia on resting metabolic rate (RMR) was studied in six normal subjects. Infusion of somatostatin (SRIH; 500 micrograms/h for 210 min) resulted in a 5-fold decrease in plasma C-peptide and a 2-fold decrease in plasma insulin and glucagon concentrations, but did not change RMR significantly. When glucagon (0.2 micrograms/kg X h), was infused with SRIH (500 micrograms/h for 210 min), the decreases in plasma C-peptide and insulin were similar to that during the infusion of SRIH alone, but plasma glucagon increased from 160 +/- 24 (+/- SEM) to 560 +/- 80 pg/mL (P less than 0.001). There was a significant increase in RMR during the entire period (210 min) of glucagon infusion (P less than 0.01). During the last hour of the glucagon plus SRIH infusion, the RMR was 1.38 +/- 0.10 Cal/min, which was 15% higher than the preinfusion RMR (1.19 +/- 0.10 Cal/min; P less than 0.01) and 14% higher than the RMR during the same period when SRIH alone was infused (1.21 +/- 0.11 Cal/min; P less than 0.01). When SRIH and glucagon were infused, protein oxidation (calculated from urinary nitrogen loss) was 52 +/- 5 mg/min, 29% higher than when SRIH alone was infused (40 +/- 5 mg/min; P less than 0.05). These results indicate that hyperglucagonemia during insulin deficiency results in an increase in energy expenditure, which may contribute to the catabolic state in many conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides, small-scale studies support the ability of glucagon receptor activation to increase metabolic rate in both fed and fasted conditions, making the glucagoneglucagon receptor axis an attractive therapeutic approach to combine with anti-obesity medications that work by reducing caloric intake (Nair, 1987;Tan et al, 2013;Salem et al, 2016;Stahel et al, 2019).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Nair, 1987
In the citing paper
“Moreover, glucagon, whose effects on blood glucose counteract insulin's, has a thermogenic effect (50).”
From Altered mitochondrial function in insulin-deficient and insulin-resistant states (2018) · cites this paper as [50]
Citations
Cites
Still being checked.
Cited by
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Notably, while several studies support that glucagon also affects energy expenditure in humans (89, 449), the contribution of the brown adipose tissue in mediating these effects in humans remains to be determined.”
BackgroundThe metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
The Glucagonoma Syndrome Clinical and Pathologic Features in 21 Patients
Wermers, R. A., Fatourechi, V., Wynne, A. G., Kvols, L. K., & Lloyd, R. V. (1996) · Medicine · doi:10.1097/00005792-199603000-00002 · Cited by 322
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
“GLP-1 (7-37) HAEGT FTSDV SSYLE GQAAK EFIAW LVKGR G”
BackgroundBrown Adipose Tissue—A Translational Perspective
Carpentier, A. C., Blondin, D. P., Haman, F., & Richard, D. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac015 · Cited by 198
Altered mitochondrial function in insulin-deficient and insulin-resistant states
Ruegsegger, G. N., Creo, A. L., Cortes, T. M., Dasari, S., & Nair, K. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120843 · Cited by 202
“Moreover, glucagon, whose effects on blood glucose counteract insulin’s, has a thermogenic effect (50).”
Self-citationObesity: Current and potential pharmacotherapeutics and targets
Narayanaswami, V., & Dwoskin, L. P. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 186
Adaptive thermogenesis with weight loss in humans
Müller, M. J., & Bosy‐Westphal, A. (2013) · Obesity · doi:10.1002/oby.20027 · Cited by 181
The role of the gut/brain axis in modulating food intake
Sam, A. H., Troke, R. C., Tan, T. M., & Bewick, G. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.008 · Cited by 167
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Hædersdal, S., Andersen, A., Knop, F. K., & Vilsbøll, T. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00817-4 · Cited by 176
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
“Additionally, glucagon has the ability to significantly increase energy expenditure during infusion in man (4,5) and has been reported to promote nonshivering thermogenesis in brown adipose tissue in rodents (6).”
BackgroundTargeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Predictive Equations for Energy Needs for the Critically Ill
Walker, R., & Heuberger, R. (2009) · Respiratory Care · doi:10.4187/respcare.09540509 · Cited by 153
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Minireview: Glucagon in Stress and Energy Homeostasis
Jones, B. J., Tan, T., & Bloom, S. R. (2012) · Endocrinology · doi:10.1210/en.2011-1979 · Cited by 140
Hormonal control of substrate cycling in humans.
Miyoshi, H., Shulman, G. I., Peters, E. J., Wolfe, M. H., Elahi, D., & Wolfe, R. R. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113487 · Cited by 139
Evidence for a catabolic role of glucagon during an amino acid load.
Charlton, M. R., Adey, D. B., & Nair, K. S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118782 · Cited by 128
Self-citationMcCarty, M. F. (1999) · Medical Hypotheses · doi:10.1054/mehy.1999.0784 · Cited by 137
Karakelides, H., Asmann, Y. W., Bigelow, M. L., Short, K. R., Dhatariya, K., Coenen-Schimke, J., Kahl, J., Mukhopadhyay, D., & Nair, K. S. (2007) · Diabetes · doi:10.2337/db07-0378 · Cited by 123
“Glucagon has also been shown to increase O2 consumption during insulin deficiency in nondiabetic healthy people (26).”
BackgroundSelf-citationGlucagon-Induced Acetylation of Foxa2 Regulates Hepatic Lipid Metabolism
von Meyenn, F., Porstmann, T., Gasser, E., Selevsek, N., Schmidt, A., Aebersold, R. H., & Stoffel, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.014 · Cited by 130
Parker, J. A., McCullough, K. A., Field, B. C. T., Minnion, J. S., Martin, N. M., Ghatei, M. A., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.227 · Cited by 111
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Physiological Mechanisms in the Adaptive Response of Metabolic Rates to Energy Restriction
Shetty, P. S. (1990) · Nutrition Research Reviews · doi:10.1079/nrr19900006 · Cited by 108
Protein Metabolism in Insulin-Dependent Diabetes Mellitus ,
Charlton, M., & Nair, K. S. (1998) · Journal of Nutrition · doi:10.1093/jn/128.2.323s · Cited by 105
Self-citationGlucagon Control on Food Intake and Energy Balance
Al-Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163905 · Cited by 88
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“The ability of glucagon to increase energy expenditure was first demonstrated in rats in 1960 [57] and was subsequently confirmed in different species including humans [58], although one study reported that glucagon infusion over 72 h did not increase energy expenditure in healthy individuals with overweight or obesit…”
Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Stern, J. H., Campbell, J. E., Scherer, P. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.011 · Cited by 88
Protein and energy metabolism in type 1 diabetes
Hebert, S. L., & Nair, K. S. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.09.001 · Cited by 89
Self-citationGlucagon regulation of energy metabolism
Heppner, K. M., Habegger, K. M., Day, J. W., Pfluger, P. T., Pérez–Tilve, D., Ward, B., Gelfanov, V. M., Woods, S. C., DiMarchi, R. D., & Tschöp, M. H. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.03.019 · Cited by 98
Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“The enhanced metabolic rate observed with glucagon administration was shown early on in rodents and humans (36, 40).”
BackgroundThe effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Energy Expenditure in Hospitalized Patients: Implications for Nutritional Support
Miles, J. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.6.809 · Cited by 76
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
The role of glucagon in the control of protein and amino acid metabolism in vivo
Flakoll, P. J., Borel, M. J., Wentzel, L. S., Williams, P. E., Lacy, D. B., & Abumrad, N. N. (1994) · Metabolism · doi:10.1016/0026-0495(94)90009-4 · Cited by 72
The future of incretin‐based therapy: novel avenues—novel targets
Åhrén, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01457.x · Cited by 64
Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes
Pereira, M. J., Thombare, K., Sarsenbayeva, A., Kamble, P. G., Almby, K., Lundqvist, M., & Eriksson, J. W. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110696 · Cited by 54
Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use
Taleb, N., Haidar, A., Messier, V., Gingras, V., Legault, L., & Rabasa‐Lhoret, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12789 · Cited by 59
Protein metabolism in diabetes mellitus
Abu-Lebdeh, H. S., & Nair, K. S. (1996) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(96)80741-5 · Cited by 62
Self-citationGut hormones as therapeutic agents in treatment of diabetes and obesity
Tan, T., & Bloom, S. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.005 · Cited by 66
Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes
Marroquí, L., Alonso-Magdalena, P., Merino, B., Fuentes, E., Nadal, A., & Quesada, I. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000031 · Cited by 54
Ojha, A., Ojha, U., Mohammed, R., Chandrashekar, A., & Ojha, H. (2019) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s202614 · Cited by 72
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 54
Glucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
“The effect of hyperglucagonemia on resting metabolic rate (RMR) has been studied in subjects by indirect calorimetry, indicating that there was a significant increase in RMR during glucagon infusion [25].”
BackgroundResultInsulin dissociates hepatic glucose cycling and glucagon-induced thermogenesis in man
Calles-Escandón, J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90180-5 · Cited by 52
Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.868037 · Cited by 48
Almdal, T., & Vilstrup, H. (1987) · Diabetologia · doi:10.1007/bf00295880 · Cited by 45
Differential control of muscle mass in type 1 and type 2 diabetes mellitus
Sala, D., & Zorzano, A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1954-7 · Cited by 47
Karamanakos, G., Kokkinos, A. D., Dalamaga, Μ., & Liatis, S. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00477-x · Cited by 49
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
Stimulation of protein turnover by carbohydrate overfeeding in men
Welle, S., Matthews, D. E., Campbell, R. G., & Nair, K. S. (1989) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1989.257.3.e413 · Cited by 42
Self-citationNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease
Galsgaard, K. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124049 · Cited by 43
Khare, P., Mangal, P., Baboota, R. K., Jagtap, S., Kumar, V., Singh, D. P., Boparai, R. K., Sharma, S. S., Khardori, R. K., Bhadada, S. K., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01244 · Cited by 40
Bowels control brain: gut hormones and obesity
Bewick, G. A. (2012) · Biochemia Medica · doi:10.11613/bm.2012.032 · Cited by 36
Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1
Tharakan, G., Tan, T., & Bloom, S. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.10.003 · Cited by 39
Regulation of thermogenic adipocytes during fasting and cold
Reinisch, I., Schreiber, R., & Prokesch, A. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110869 · Cited by 36
Abeyta, M. A., Al‐Qaisi, M., Horst, E. A., Mayorga, E. J., Rodríguez-Jiménez, S., Goetz, B. M., Carta, S., Tucker, H. A., & Baumgard, L. H. (2022) · Journal of Dairy Science · doi:10.3168/jds.2022-22338 · Cited by 38
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
Cegla, J., Jones, B. J., Gardiner, J. V., Hodson, D. J., Marjot, T., McGlone, E. R., Tan, T. M., & Bloom, S. R. (2017) · Endocrinology · doi:10.1210/en.2016-1755 · Cited by 36
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 38
Whytock, K. L., Carnero, E. A., Vega, R. B., Tillner, J., Bock, C., Chivukula, K., Yi, F., Meyer, C., Smith, S. R., & Sparks, L. M. (2021) · Obesity · doi:10.1002/oby.23141 · Cited by 30
Claessens, M., Calame, W., Siemensma, A. D., Saris, W. H. M., & van Baak, M. A. (2007) · Metabolism · doi:10.1016/j.metabol.2007.04.001 · Cited by 32
Storage and Expenditure of Energy in Obesity and Their Implications for Management
Sims, E. A. H. (1989) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30694-0 · Cited by 33
Effects of 13-Hour Hyperglucagonemia on Energy Expenditure and Hepatic Glucose Production in Humans
Chakravarthy, M., Parsons, S., Lassman, M. E., Butterfield, K., Lee, A. Y. H., Chen, Y., Previs, S., Spond, J., Yang, S., Bock, C., et al. (2017) · Diabetes · doi:10.2337/db16-0746 · Cited by 28
Revisiting Resting Metabolic Rate: What is the Relation to Weight Fluctuations?
Argyrakopoulou, G., Fountouli, N., Dalamaga, Μ., & Kokkinos, A. D. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00528-x · Cited by 28
Elvert, R., Bossart, M., Herling, A. W., Weiss, T., Zhang, B., Kannt, A., Wagner, M., Haack, T., Evers, A., Dudda, A., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00399 · Cited by 24
James, H. A., Gonsalves, W. I., Manjunatha, S., Dasari, S., Lanza, I. R., Klaus, K. A., Vella, A. V., Andrews, J. C., & Nair, K. S. (2022) · Diabetes · doi:10.2337/db22-0079 · Cited by 23
Self-citationRole of Glucagon in Automated Insulin Delivery
Wilson, L. M., Jacobs, P. G., & Castle, J. R. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.008 · Cited by 25
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
Ruiter, M., Buijs, R. M., & Kalsbeek, A. (2006) · Current Diabetes Reviews · doi:10.2174/157339906776818596 · Cited by 24
G Protein-Coupled Receptors as Regulators of Energy Homeostasis
Tao, Y., Yuan, Z., & Xie, J. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00001-7 · Cited by 21
Pedersen, C., Porsgaard, T., Thomsen, M., ROSENKILDE, M. M., & Roed, N. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194468 · Cited by 21
Scott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 21
Effect of Diabetes Mellitus on Protein–Energy Wasting and Protein Wasting in End‐Stage Renal Disease
Noori, N., & Kopple, J. D. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00705.x · Cited by 20
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M., Rodbard, H., Sattar, N., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 20
Golubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
Multi-Target Drugs Against Metabolic Disorders
Scotti, L., Monteiro, A., Viana, J. D. O., Mendonça, F. J. B., Ishiki, H. M., Ernestine, N., Santos, R., & Scotti, M. T. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666181217123357 · Cited by 19
Freyse, E., Fischer, U., Knospe, S., Ford, G. C., & Nair, K. S. (2006) · Diabetologia · doi:10.1007/s00125-005-0062-x · Cited by 18
Self-citationMcCarty, M. F., & Gustin, J. C. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0683 · Cited by 18
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Vansant, G. A. A. M., Gaal, L. V., Acker, K. L. V., & Leeuw, I. D. (1991) · Metabolism · doi:10.1016/0026-0495(91)90082-8 · Cited by 16
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
Heat stress alters hematological parameters in barrows and gilts
Rudolph, T. E., Roths, M. S., Freestone, A. D., White-Springer, S. H., Rhoads, R. P., Baumgard, L. H., & Selsby, J. T. (2024) · Journal of Animal Science · doi:10.1093/jas/skae123 · Cited by 16
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
A glucagon analogue decreases body weight in mice via signalling in the liver
Hinds, C. E., Owen, B. M., Hope, D. C. D., Pickford, P., Jones, B. J., Tan, T., MINNION, J. S., & Bloom, S. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-01912-0 · Cited by 15
Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 17
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
Metadata
- Authors
- NAIR, K. S.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- NAIR, K. SREEKUMARAN
- ORCID
- NAIR, K. SREEKUMARAN
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1987-05
- Volume
- 64
- Issue
- 5
- Pages
- 896-901
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2085655607
- Cited by
- 141
- References
- 0
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 9 · 2023: 10 · 2022: 12 · 2021: 6 · 2020: 5 · 2019: 15 · 2018: 11 · 2017: 3 · 2016: 6 · 2015: 2 · 2014: 3 · 2013: 10 · 2012: 3
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AM-20494)
- National Center for Research Resources (RR-00044, RR05403)
- NIH Clinical Center
- Rocky Mountain Research Station
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- hyperglucagonemia, resting metabolic rate, insulin deficiency, somatostatin, glucagon infusion, C-peptide, protein oxidation, energy expenditure, catabolic state, urinary nitrogen loss
- MeSH terms
- Adult, Basal Metabolism, Blood Glucose, C-Peptide, Energy Metabolism, Female, Glucagon, Humans, Insulin, Kinetics, Male, Oxygen Consumption, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.